Research & Innovation - Participant Portal



Topic identifier: IMI2-2015-07-07
Publication date: 18 December 2015

Types of action: IMI2-RIA Research and Innovation action
Opening date:
18 December 2015
2nd stage Deadline:
17 March 2016 17:00:00
06 September 2016 17:00:00

Time Zone : (Brussels time)
  Horizon 2020 H2020 website
Pillar: Societal Challenges
Work Programme Year: H2020-JTI-IMI-2016
Work Programme Part: IMI2 Work Plan 2016
Topic Description
Specific Challenge:

By 2020, heart disease and stroke will become the leading causes of death and disability worldwide, with the number of fatalities projected to increase to more than 24 million by 2030.

Common cardiovascular diseases - heart arrhythmias (primarily atrial fibrillation or AF), heart failure (HF) and acute coronary syndrome (ACS) – cause much of this disability. While major advances in the management of these diseases have been achieved, medical management of these cardiovascular patients remains challenging. Current treatment guidelines are often not followed, leaving many patients not or undertreated.

Guideline committees call for more data to inform management recommendations. Ultimately, these data should aid the development of new medications, interventions and targeted management recommendations that improve outcomes, in all patients but in particular in pertinent patient subgroups. Likewise, healthcare providers should have new and improved diagnostics to select the right course of treatment. Such data should also help delay these diseases to more advanced ages.

Although current technology has led to the collection of massive amounts of healthcare data, wide scale exploitation of these data sources has yet to be achieved. This is mainly due to obstacles in the linkage of data, which results in fragmented and isolated datasets. Disease registries capturing incident cases are rare as many patient registries are designed for healthcare administration purposes whereas information on incident cases is crucial for studies of the aetiology and for studies of baseline characterization of patients.

Powerful insights could be generated from the combination or linking of in-patient and out-patient hospital data, prescription data, sociodemographic data, clinical trial data from pharmaceutical companies and data from newer technologies and 'omic measurements under appropriate data governance respectful of privacy.


The main goal of this initiative is to improve AF, HF, and ACS patient outcomes through better access and use of data. This will require:

1.defining and prioritising relevant patient outcomes in collaboration with key healthcare system stakeholders and patients;

2.accessing and analysing relevant morbidity and mortality data from large population based healthcare databases and patient data sources;

3.collecting and analysing data from clinical studies, genotyping, protein biomarkers, advanced imaging, or quality of life information directly from patients;

4.exploring algorithms that combine traditional and newer sources of data to improve the ability to assess the risk of a patient or population for relevant cardiovascular outcomes, diagnose the subtype and biological drivers of those risks, prescribe effective treatments, and monitor for progression or regression of disease;

5.translating the insights from these analyses to disease management concepts and guidelines, and innovative drug development to improve patient outcomes.

Expected Impact:

The expected impacts of the proposed project are better and safer treatment paradigms for patients with AF, HF, and ACS. This impact should be achieved by providing evidence which will make it easier for HCPs and other stakeholders to provide the right treatment to the right patient at the right time.

Topic conditions and documents

Please read carefully all provisions below before the preparation of your application.

You can access the description of the different topics in the Call topics text.

The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section (page 78), as well as the following information : 

  1. List of countries and applicable rules for funding
  2. Eligibility and admissibility conditions
  3. Evaluation criteria and procedure, scoring and threshold : described in the IMI Manual for Submission, Evaluation and Grant award
  4. Indicative timetable for evaluation and grant agreement
  5. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

    IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):

    Summary of the most relevant provisions for participating in IMI2 actions
    Standard proposal template
    Standard evaluation form
    IMI2 Model Grant Agreement
    Template for Essential Clinical Trials Information

    MI2 Coordination and Support Action (IMI2-CSA):

    Summary of the most relevant provisions for participating in IMI2 actions
    Standard proposal template
    Standard evaluation form
    IMI2 Model Grant Agreement
    Template for Essential Clinical Trials Information


Submission Service

No submission system is open for this topic.

Get support

Contact the IMI Programme Office : E-mail: / Tel: +32 2 221 81 81

Contact IMI JU IT Helpdesk – for IMI2 topics contact the SOFIA IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

IMI States Representative Group (SRG) – contact you SRG member for assistance.

IMI Partner Search Tool
 helps you find a partner organisation for your proposal

National Contact Points (NCP) - 
contact your NCP for further assistance.

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding

Research Enquiry Service
– ask questions about. any aspect of European research in general and the EU Research Framework Programmes in particular.

– for compliance with ethical issues, check the information available on the Participant Portal , on the Science and Society Portal and in The European Charter for Researchers and the Code of Conduct for their recruitment

and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at